Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.

European journal of medicinal chemistry - 27 Jan 2017

Tomek Petr, Palmer Brian D, Flanagan Jack U, Sun Chuanwen, Raven Emma L, Ching Lai-Ming

Abstract excerpt

High expression of the immunosuppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1) for a broad range of malignancies is associated with poor patient prognosis, and the enzyme is a validated target for cancer intervention. To identify novel IDO1 inhibitors suitable for drug development, 1597 compounds in the National Cancer Institute Diversity Set III library were tested for inhibitory activity against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalytic Domain
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Enzyme Inhibitors

Share to Immune Tolerance

Share to Indoleamine-Pyrrole 2,3,-Dioxygenase

Share to Molecular Docking Simulation

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 28011425
DOI: 10.1016/j.ejmech.2016.12.029

Genes

IDO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.PMID 28011425Read ↗

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the pastSemantic proximity Read ↗

Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)Semantic proximity Read ↗

The Kynurenine Pathway and Cancer: Why Keep It Simple When You Can Make It ComplicatedSemantic proximity Read ↗

Role of indoleamine 2,3-dioxygenase in health and diseaseSemantic proximity Read ↗

Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.Semantic proximity Read ↗

Indoleamine 2,3-Dioxygenase 2 (IDO2): The Protein That Lived TwiceSemantic proximity Read ↗

Current Challenges for IDO2 as Target in Cancer ImmunotherapySemantic proximity Read ↗

Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics.Semantic proximity Read ↗

Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer diseaseSemantic proximity Read ↗

The immunosuppressive enzyme IL4I1 promotes FoxP3(+) regulatory T lymphocyte differentiation.Semantic proximity Read ↗

Natural CD4+ T-Cell Responses against Indoleamine 2,3-DioxygenaseSemantic proximity Read ↗

Indoleamine 2,3-Dioxygenase and Dendritic Cell TolerogenicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.